EMA Recommends Caution For Pfizer's Xeljanz

The Agency Has Also Issued Restrictions For Sanofi's Lemtrada

 
• By Neena Brizmohun
  
Healthy human red bloodcells abstract concept background - Image
The EMA warns that Xeljanz can cause blood clots in high-risk patients • Source: Shutterstock

More from Europe

More from Geography